News on menopausal hormone therapy
- Authors: Demidova T.Y.1, Zenina S.G2, Gasanzade P.A2
-
Affiliations:
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Issue: Vol 20, No 4 (2018)
- Pages: 47-51
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/95018
- DOI: https://doi.org/10.26442/2075-1753_2018.4.47-51
- ID: 95018
Cite item
Full Text
Abstract
About 1/3 of a modern woman's life falls on menopause. Perimenopausal transition period is a critical period and it is essential to inform patients on possibilities of modern hormone therapy that allows not only to manage unfavorable menopausal symptoms and estrogen deficiency consequences but also to maintain woman's social activity and improve her quality of life. The article presents contemporary view on menopausal hormone therapy based on most recent relevant guidelines.
Full Text
##article.viewOnOriginalSite##About the authors
T. Yu Demidova
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: t.y.demidova@gmail.com
д-р мед. наук, проф., зав. каф. эндокринологии лечебного фак-та 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
S. G Zenina
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federationврач-ординатор каф. эндокринологии 123995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1 *t.y.demidova@gmail.com
P. A Gasanzade
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federationврач-ординатор каф. эндокринологии 123995, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1 *t.y.demidova@gmail.com
References
- Harlow S.D, Gass M, Hall J.E et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012; 15 (2): 105-14.
- Rossouw J.E, Anderson G.L, Prentice R.L et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
- Rossouw J.E, Prentice R.L, Manson J.E et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297: 1465-77.
- Cobin R.H, Goodman N.F et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on menopause-2017 Update. Endocrine Practice 2017; 23 (7): 869-79.
- Santen R.J, Allred D.C, Ardoin S.P et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95: s1-s66.
- Maclennan A.H, Broadbent J.L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; 4: CD002978.
- Stuenkel C.A, Davis S.R, Gompel A et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100 (11): 3975-4011.
- Shao H, Breitner J.C, Whitmer R.A et al. Hormone therapy and Alzheimer disease dementia: new findings from the Cache County Study. Neurology 2012; 79: 1846-52.
- Manson J.E, Chlebowski R.T, Stefanick M.L et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-68.
- National Osteoporosis Foundation. 2014 Clinician’s Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2791/upload/919.pdf
- Boardman H.M, Hartley L, Eisinga A et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015; 3: CD002229.
- Files J.A, Ko M.G, Pruthi S. Bioidentical hormone therapy. Mayo Clin Proc 2011; 86: 673-80.
Supplementary files
